rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    HCM
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      HUTCHMED at Deutsche Bank conference: pipeline wins and cash strength
      Nov 12Investing.comHCMDB
      Should Phase III Lung Cancer Data Require Action From Hutchmed (AIM:HCM) Investors?

      HUTCHMED (China) reported that ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) delivered statistically significant progression free and overall survival benefits in the Phase III SAFFRON and SANOVO lung cancer trials. Regulatory filings for the combination have been accepted in Europe and Japan, following prior submissions in the US and existing approvals in China and Switzerland. The same savolitinib and TAGRISSO combination now spans late stage global data, multiple commercial...

      Nov 8Yahoo FinanceHCM
      HUTCHMED (China) (AIM:HCM) Extends Lung Cancer Filing Run As Undervalued View Holds
      Nov 6Yahoo FinanceHCM
      HUTCHMED (AIM:HCM) Stock May Look Rich As FDA Orphan Drug News Lands

      HUTCHMED (China) has seen its share price fall sharply in recent years, even as it continues to advance its drug pipeline, which raises a straightforward question for investors who follow HUTCHMED closely. Is the current valuation of the stock well aligned with what the business is earning today and what those earnings suggest about its long term potential? Over the past 5 years the share price has declined 54.8%, which puts the focus squarely on whether the current earnings base can support...

      Nov 3Yahoo FinanceHCM
      HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan

      — Follows US FDA new drug application submission in September 2026, marking important global regulatory progress — — Filings supported by positive SAFFRON global Phase III data demonstrating statistically significant and clinically meaningful PFS and OS improvements — — Data selected for ESMO 2026 Presidential Symposium and simultaneously published in The New England Journal of Medicine — HONG KONG and FLORHAM PARK, N.J., Nov. 01, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (N

      Nov 2Yahoo FinanceHCM
      Bank of America Securities Keeps Their Buy Rating on HUTCHMED (HCM)

      Tipranks Press Release.

      Oct 27The Globe and MailHCM
      Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer
      Oct 27Yahoo FinanceHCM
      HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine

      — ORPATHYS® plus TAGRISSO® reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO® — — ORPATHYS® plus TAGRISSO® extended median OS by nearly 5 months — — SAFFRON is the first global Phase III trial to show significant progression-free and overall survival benefit in this setting — — Establishes ORPATHYS® plus TAGRISSO® as an important targeted strategy to address MET-driven resistance following pro

      Oct 26Yahoo FinanceHCM
      What HUTCHMED (China) (AIM:HCM)'s GSK Licensing Deal Means For Shareholders
      Oct 25Yahoo FinanceHCM
      GSK (LSE:GSK) Secures Ex China Rights To KRAS EGFR Cancer Drug
      Oct 23Yahoo FinanceHCMGSK
      HUTCHMED closes $110M licensing deal with GSK for cancer therapy
      Oct 21Investing.comHCMGSK
      HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China
      Oct 21Yahoo FinanceHCMGSK
      HUTCHMED (AIM:HCM) Stock Looks Expensive Relative To Current Earnings
      Oct 18Yahoo FinanceHCM
      How Investors May Respond To HUTCHMED (China) (AIM:HCM) US NDA For ORPATHYS–TAGRISSO Lung Cancer Combo
      Oct 13Yahoo FinanceHCM
      HUTCHMED submits US application for lung cancer combination
      Sep 29Investing.comHCM
      AstraZeneca files for US FDA approval of HUTCHMED lung cancer drug combination
      Sep 29ReutersHCM
      HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer

      — Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors have MET overexpression or amplification, after progression on an EGFR-TKI therapy — — Application supported by SAFFRON, the first global Phase III trial to demonstrate statistically significant and clinically meaningful improvements in progression-free and overall survival in this setting — — SAFFRON builds on evidence from the SACHI Phase III and SAVANNAH Phase II trials — HONG KONG, SHANGHAI

      Sep 29Yahoo FinanceHCM
      AstraZeneca files for US FDA approval of HUTCHMED lung cancer drug combination
      Sep 28Yahoo FinanceAZNHCM
      Hutchmed Doses First Patient in Early-Stage Trial of HMPL-A830 for Solid Tumors

      Hutchmed (HMC) has dosed the first patient in the phase 1a portion of a global clinical trial of HMP

      Sep 28Yahoo FinanceHCM
      Why is HUTCHMED China stock gaining today?
      Sep 28Investing.comHCM
      HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
      Sep 28Yahoo FinanceHCM
      HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
      Sep 27Yahoo FinanceHCM
      GSK Bets on HUTCHMED to Expand its Multi-Billion-Dollar Oncology Opportunity

      On September 3, HUTCHMED (China) Limited (NASDAQ:HCM) announced an exclusive global development and licensing agreement with GSK plc (NYSE:GSK) for HMPL-A830, targeting colorectal, pancreatic, and lung cancers. Under the agreement, HUTCHMED receives a $110 million upfront payment, potential milestone payments up to $1.3 billion, and tiered royalties on net sales, while granting GSK worldwide rights […]

      Sep 24Yahoo FinanceHCMGSK
      HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026
      Sep 23Yahoo FinanceHCM
      BofA Adjusts Price Target on HUTCHMED (China) to $18 From $16, Keeps Buy Rating
      Sep 21Yahoo FinanceHCM
      HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology Asset A830 - Slideshow (NASDAQ:HCM) 2026-09-07
      Sep 19Seeking AlphaHCM
      HUTCHMED (China) Reports H1 2026 Results: Full Earnings Call Transcript - HUTCHMED (China) (NASDAQ:HCM)

      HUTCHMED (China) (NASDAQ:HCM) released quarterly financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to

      Sep 18BenzingaHCM
      HUTCHMED (China) Reports H1 2026 Results: Full Earnings Call Transcript
      Sep 18BenzingaHCM
      CICC Sticks to Their Buy Rating for HUTCHMED (China) (HCM)

      Detailed price information for Hutchmed China Ltd ADR (HCM-Q) from The Globe and Mail including charting and trades.

      Sep 9The Globe and MailHCM
      Citic Securities Remains a Buy on HUTCHMED (China) (HCM)

      Detailed price information for Hutchmed China Ltd ADR (HCM-Q) from The Globe and Mail including charting and trades.

      Sep 9The Globe and MailHCM
      Huatai Securities Keeps Their Buy Rating on HUTCHMED (China) (HCM)

      Detailed price information for Hutchmed China Ltd ADR (HCM-Q) from The Globe and Mail including charting and trades.

      Sep 8The Globe and MailHCM
      HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology Asset A830 - Slideshow (NASDAQ:HCM) 2026-09-07
      Sep 7Seeking AlphaHCMGSK
      Adlai Nortye's KRAS Opportunity Further Validated by GSK-Hutchmed Deal, Oppenheimer Says
      Sep 4Yahoo FinanceANLHCM
      Why Is HUTCHMED Stock Soaring Thursday?
      Sep 3BenzingaHCMGSK
      HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy

      HUTCHMED (NASDAQ:HCM) said it has entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted therapy conjugate, or ATTC. The transaction has a total potential value of approximately $1.3 billion, including a $110 million upfr

      Sep 3Yahoo FinanceHCMGSK
      Why is HUTCHMED stock surging today?
      Sep 3Investing.comHCM
      Summit Therapeutics, HUTCHMED, Tesla And Other Big Stocks Moving Higher On Thursday
      Sep 3BenzingaHCMSMMT
      Panmure and Cavendish reiterate buy on Hutchmed after GSK deal

      Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) won ringing endorsements from City brokers on Thursday after securing a blockbuster licensing agreement with GSK PLC (LSE:GSK, NYSE:GSK), exposing what analysts regard as a deep valuation disconnect. The shares leapt 15% to...

      Sep 3Yahoo FinanceHCMGSK
      HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal

      Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares jumped 17% to 210p on Thursday after the oncology specialist struck a licensing agreement with GSK worth up to US$1.295 billion for its experimental KRAS-EGFR cancer therapy. HUTCHMED will receive US$110 million upfront and...

      Sep 3Yahoo FinanceHCM
      GSK licenses HUTCHMED’s solid tumour conjugate in up to $1.3bn deal
      Sep 3Yahoo FinanceHCM
      GSK wagers up to $1.3B on a different kind of cancer drug
      Sep 3Yahoo FinanceHCM
      HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug
      Sep 3ReutersHCMGSK
      HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy

      — Exclusive License for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (“ATTC”), which is expected to enter clinical trials in H2 2026 —— HUTCHMED webcasts today at 4:30 p.m. HKT in Chinese (Putonghua) and at 7:30 a.m. EDT / 12:30 p.m. BST / 7:30 p.m. HKT in English — HONG KONG and FLORHAM PARK, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that its subsidiary, HUTCHMED Limited, has entered in

      Sep 3Yahoo FinanceHCMGSK
      HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy

      — Exclusive License for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (“ATTC”), which is expected to enter clinical trials in H2 2026 —— HUTCHMED webcasts today at 4:30 p.m. HKT in Chinese (Putonghua) and at 7:30 a.m. EDT / 12:30 p.m. BST / 7:30 p.m. HKT in English — HONG KONG and FLORHAM PARK, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that its subsidiary, HUTCHMED Limited, has entered in

      Sep 2Yahoo FinanceHCM
      AstraZeneca and HUTCHMED report Phase III results for Tagrisso-Orpathys combination

      AstraZeneca (LSE:AZN) and HUTCHMED reported results from the SANOVO Phase III trial in China evaluating Tagrisso in combination with Orpathys as a first-line treatment for certain patients with non-small cell lung cancer. The trial showed a statistically significant and clinically meaningful improvement in progression-free survival for the combination compared with Tagrisso alone in treatment-naïve patients with EGFR-mutated, MET-overexpressing non-small cell lung cancer.

      Sep 1Yahoo FinanceAZNHCM
      AstraZeneca-Hutchmed drug combination shows promise in advanced lung cancer study
      Sep 1ReutersAZNHCM
      HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China

      Findings build on the established success of the global SAFFRON and China SACHI trials, extending the clinical value of the all-oral combination into the first-line settingHONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED“) (Nasdaq/AIM: HCM; HKEX: 13) today announces positive high-level results from the SANOVO China Phase III trial in treatment-naïve patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”

      Aug 31Yahoo FinanceHCM
      HUTCHMED receives China approval for cholangiocarcinoma drug
      Aug 28Investing.comHCM
      HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma

      Novel, highly potent oral selective FGFR 1/2/3 inhibitor approved for patients with advanced FGFR2-altered intrahepatic cholangiocarcinoma in ChinaHONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 27, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (NDA) for fanregratinib (HMPL-453), a novel, selective, oral inhibitor targeting FGFR 1/2/3, has been granted conditional approval by the China National Medical P

      Aug 28Yahoo FinanceHCM
      Sinolink Securities Remains a Buy on HUTCHMED (China) (HCM)

      Detailed price information for Hutchmed China Ltd ADR (HCM-Q) from The Globe and Mail including charting and trades.

      Aug 23The Globe and MailHCM

      This is the newest page. Registered accounts read further back.